参考文献
［1］Vaccarella S,Franceschi S,Bray F,et al.Worldwide thyroid-cancer epidemic?The increasing impact of overdiagnosis[J].N Engl J Med,2016,375（7）:614-617.
［2］Seib CD,Sosa JA.Evolving Understanding of the epidemiology of thyroid cancer[J].Endocrinol Metab Clin North Am,2019,48（1）:23-35.
［3］Micali C,Russotto Y,Celesia BM,et al.Thyroid diseases and thyroid asymptomatic dysfunction in people living with HIV[J].Infect Dis Rep,2022,14（5）:655-667.
［4］Hulbert A,Hooker CM,Keruly JC,et al.Prospective CT screening for lung cancer in a high-risk population:HIV-positive smokers[J].J Thorac Oncol,2014,9（6）:752-759.
［5］Pizzato M,Li M,Vignat J,et al.The epidemiological landscape of thyroid cancer worldwide:GLOBOCAN estimates for incidence and mortality rates in 2020[J].Lancet Diabetes Endocrinol,2022,10（4）:264-272.
［6］Wang F,Xiang P,Zhao H,et al.A retrospective study of distribution of HIV associated malignancies among inpatients from 2007 to 2020 in China[J].Sci Rep,2021,11（1）:24353.
［7］Park B,Ahn KH,Choi Y,et al.Cancer incidence among adults with HIV in a population-based cohort in Korea[J].JAMA Netw Open,2022,5（8）:e2224897.
［8］Hernandez-Ramirez RU,Shiels MS,et al.Cancer risk in HIV-infected people in the USA from 1996 to 2012:a population-based,registry-linkage study[J].Lancet HIV,2017,4（11）:e495-e504.
［9］Properzi M,Della GT,Mentasti S,et al.Low prevalence of symptomatic thyroid diseases and thyroid cancers in HIV-infected patients[J].Sci Rep,2019,9（1）:19459.
［10］Muller I,Moran C,Lecumberri B,et al.2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy[J].Eur Thyroid J,2019,8（4）:173-185.(https://www.daowen.com)
［11］Takano T.Fetal cell carcinogenesis of the thyroid:a modified theory based on recent evidence[J].Endocr J,2014,61（4）:311-320.
［12］Prete A,Borges De Souza P,Censi S,et al.Update on fundamental mechanisms of thyroid cancer[J].Frontiers in Endocrinology,2020,11（3）:102.
［13］Hong JT,Son DJ,Lee CK,et al.Interleukin 32,inflammation and cancer.Pharmacol[J].Therapeut,2017,174（6）:127-137.
［14］Haddad RI,Nasr C,Bischoff L,et al.NCCN guidelines insights:Thyroid carcinoma,version 2.2018[J].J Natl Compr Canc Netw,2018,16（12）:1429-1440.
［15］Haugen BR,Alexander EK,Bible KC,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26（1）:1-133.
［16］裘法祖，黄家驷.外科学［M］.7版，北京：人民卫生出版社，2007.
［17］Nabhan F,Ringel MD.Thyroid nodules and cancer management guidelines:comparisons and controversies[J].Endocr Relat Cancer,2017,24（2）:R13-R26.
［18］Ito Y,Miyauchi A,Inoue H,et al.An observational trial for papillary thyroid microcarcinoma in Japanese patients[J].World J Surg,2010,34（1）:28-35.
［19］Brito JP,Ito Y,Miyauchi A,et al.A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma[J].Thyroid,2016,26（1）:144-149.